Influenza A Virus, H1N1 Subtype Infections Pipeline Review, H1 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017" report to their offering.

Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 8, 7, 1, 41 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 11 and 3 molecules, respectively.

Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Influenza A Virus, H1N1 Subtype Infections - Overview
  3. Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Akshaya Bio Inc
  • Altimmune Inc
  • Antigen Express Inc
  • Beijing Minhai Biotechnology Co Ltd
  • CEL-SCI Corp
  • Cilian AG
  • Cocrystal Pharma Inc
  • ContraFect Corp
  • Curevac AG
  • EpiVax Inc
  • Etubics Corp
  • Gemmus Pharma Inc
  • Genentech Inc
  • iBio Inc
  • ILiAD Biotechnologies LLC
  • Kineta Inc
  • Kyowa Hakko Kirin Co Ltd
  • Lakewood-Amedex Inc
  • Medicago Inc
  • MedImmune LLC
  • Microbiotix Inc
  • Mucosis BV
  • NanoViricides Inc
  • NewLink Genetics Corp
  • Novavax Inc
  • Protein Sciences Corp
  • Recce Ltd
  • Sanofi Pasteur SA
  • Sarepta Therapeutics Inc
  • SK Chemicals Co Ltd
  • Takeda Pharmaceutical Company Ltd
  • TechnoVax Inc
  • Touchlight Genetics Ltd
  • Zydus Cadila Healthcare Ltd

For more information about this report visit http://www.researchandmarkets.com/research/vqnpgw/influenza_a

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs